Cite
Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
MLA
Tanizaki, Junko, et al. “Case Report: Durable Response to Afatinib in a Patient with Lung Cancer Harboring Two Uncommon Mutations of EGFR and a KRAS Mutation.” Lung Cancer (01695002), vol. 101, Nov. 2016, pp. 11–15. EBSCOhost, https://doi.org/10.1016/j.lungcan.2016.09.001.
APA
Tanizaki, J., Banno, E., Togashi, Y., Hayashi, H., Sakai, K., Takeda, M., Kaneda, H., Nishio, K., & Nakagawa, K. (2016). Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation. Lung Cancer (01695002), 101, 11–15. https://doi.org/10.1016/j.lungcan.2016.09.001
Chicago
Tanizaki, Junko, Eri Banno, Yosuke Togashi, Hidetoshi Hayashi, Kazuko Sakai, Masayuki Takeda, Hiroyasu Kaneda, Kazuto Nishio, and Kazuhiko Nakagawa. 2016. “Case Report: Durable Response to Afatinib in a Patient with Lung Cancer Harboring Two Uncommon Mutations of EGFR and a KRAS Mutation.” Lung Cancer (01695002) 101 (November): 11–15. doi:10.1016/j.lungcan.2016.09.001.